332 related articles for article (PubMed ID: 24504546)
1. Prognostic biomarkers in endometrial and ovarian carcinoma.
Matias-Guiu X; Davidson B
Virchows Arch; 2014 Mar; 464(3):315-31. PubMed ID: 24504546
[TBL] [Abstract][Full Text] [Related]
2. Molecular-based classification algorithm for endometrial carcinoma categorizes ovarian endometrioid carcinoma into prognostically significant groups.
Parra-Herran C; Lerner-Ellis J; Xu B; Khalouei S; Bassiouny D; Cesari M; Ismiil N; Nofech-Mozes S
Mod Pathol; 2017 Dec; 30(12):1748-1759. PubMed ID: 28776572
[TBL] [Abstract][Full Text] [Related]
3. [Clinicopathologic and survival analysis of synchronous primary endometrial and ovarian cancer].
Wang Y; Yu M; Yang JX; Cao DY; Zhang Y; Shen K; You Y
Zhonghua Fu Chan Ke Za Zhi; 2018 Dec; 53(12):816-822. PubMed ID: 30585019
[No Abstract] [Full Text] [Related]
4. Prognostic impact of concomitant p53 and PTEN on outcome in early stage (FIGO I-II) epithelial ovarian cancer.
Skírnisdóttir I; Seidal T
Int J Gynecol Cancer; 2011 Aug; 21(6):1024-31. PubMed ID: 21792012
[TBL] [Abstract][Full Text] [Related]
5. Morphologic, Immunophenotypic, and Molecular Features of Epithelial Ovarian Cancer.
Ramalingam P
Oncology (Williston Park); 2016 Feb; 30(2):166-76. PubMed ID: 26892153
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of DNA topoisomerase II-alpha (Ki-S1) immunoexpression in endometrial carcinoma.
Bildrici K; Tel N; Ozalp SS; Yalcin OT; Yilmaz V
Eur J Gynaecol Oncol; 2002; 23(6):540-4. PubMed ID: 12556100
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive analysis of PD-L1 expression, HER2 amplification, ALK/EML4 fusion, and mismatch repair deficiency as putative predictive and prognostic factors in ovarian carcinoma.
Schmoeckel E; Hofmann S; Fromberger D; Rottmann M; Luthardt B; Burges A; Jeschke U; Kirchner T; Lax SF; Mayr D
Virchows Arch; 2019 May; 474(5):599-608. PubMed ID: 30734108
[TBL] [Abstract][Full Text] [Related]
8. The ARID1A, p53 and ß-Catenin statuses are strong prognosticators in clear cell and endometrioid carcinoma of the ovary and the endometrium.
Heckl M; Schmoeckel E; Hertlein L; Rottmann M; Jeschke U; Mayr D
PLoS One; 2018; 13(2):e0192881. PubMed ID: 29451900
[TBL] [Abstract][Full Text] [Related]
9. Morphological and Immunohistochemical Reevaluation of Tumors Initially Diagnosed as Ovarian Endometrioid Carcinoma With Emphasis on High-grade Tumors.
Lim D; Murali R; Murray MP; Veras E; Park KJ; Soslow RA
Am J Surg Pathol; 2016 Mar; 40(3):302-12. PubMed ID: 26551621
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors of synchronous endometrial and ovarian endometrioid carcinoma.
Yoneoka Y; Yoshida H; Ishikawa M; Shimizu H; Uehara T; Murakami T; Kato T
J Gynecol Oncol; 2019 Jan; 30(1):e7. PubMed ID: 30479091
[TBL] [Abstract][Full Text] [Related]
11. [Recent advances on ovarian epithelial cancer: definition, subtypes and pathologic features].
Guo DH; Zheng WX
Zhonghua Bing Li Xue Za Zhi; 2013 Sep; 42(9):624-8. PubMed ID: 24314254
[No Abstract] [Full Text] [Related]
12. L1CAM expression associates with poor outcome in endometrioid, but not in clear cell ovarian carcinoma.
Soovares P; Pasanen A; Bützow R; Lassus H
Gynecol Oncol; 2017 Sep; 146(3):615-622. PubMed ID: 28625395
[TBL] [Abstract][Full Text] [Related]
13. Synchronous tumours of the female reproductive tract.
Gilks CB; Kommoss F
Pathology; 2018 Feb; 50(2):214-221. PubMed ID: 29249564
[TBL] [Abstract][Full Text] [Related]
14. Histopathological characterization of ProMisE molecular groups of endometrial cancer.
Raffone A; Travaglino A; Mascolo M; Carotenuto C; Guida M; Mollo A; Insabato L; Zullo F
Gynecol Oncol; 2020 Apr; 157(1):252-259. PubMed ID: 31932106
[TBL] [Abstract][Full Text] [Related]
15. Synchronous primary ovarian and endometrial cancer with a fair prognosis in a young woman.
Yang YH; Chen RJ; Lin MC; Cheng SP; Chang TC
Taiwan J Obstet Gynecol; 2010 Mar; 49(1):97-100. PubMed ID: 20466303
[No Abstract] [Full Text] [Related]
16. Seromucinous component in endometrioid endometrial carcinoma as a histological predictor of prognosis.
Miyamoto M; Takano M; Aoyama T; Soyama H; Yoshikawa T; Tsuda H; Furuya K
J Gynecol Oncol; 2018 Mar; 29(2):e20. PubMed ID: 29400013
[TBL] [Abstract][Full Text] [Related]
17. [Relationships between the molecular biomarkers and the clinicopathologic features and prognosis in endometrial carcinoma].
Yao YY; Xu WZ; Wang Y; Shen DH; Wang JL; Wei LH
Beijing Da Xue Xue Bao Yi Xue Ban; 2011 Oct; 43(5):743-8. PubMed ID: 22008688
[TBL] [Abstract][Full Text] [Related]
18. Cancer stem cell and embryonic development-associated molecules contribute to prognostic significance in ovarian cancer.
Oktem G; Sanci M; Bilir A; Yildirim Y; Kececi SD; Ayla S; Inan S
Int J Gynecol Cancer; 2012 Jan; 22(1):23-9. PubMed ID: 22080880
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of tissue protein expression levels of MIB-1 (Ki-67) in Danish ovarian cancer patients. From the 'MALOVA' ovarian cancer study.
Heeran MC; Høgdall CK; Kjaer SK; Christensen L; Jensen A; Blaakaer J; Christensen IJ; Høgdall EV
APMIS; 2013 Dec; 121(12):1177-86. PubMed ID: 23594232
[TBL] [Abstract][Full Text] [Related]
20. [Histological grading of epithelial ovarian cancer. Review and recommendation].
Hauptmann S; du Bois A; Meinhold-Herlein I; Pfisterer J; Avril S
Pathologe; 2014 Sep; 35(5):497-503. PubMed ID: 25069848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
